Creative Planning Has $1.22 Million Position in Evolent Health, Inc. (NYSE:EVH)

Creative Planning lifted its stake in Evolent Health, Inc. (NYSE:EVH - Free Report) by 139.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,262 shares of the technology company's stock after acquiring an additional 25,171 shares during the period. Creative Planning's holdings in Evolent Health were worth $1,223,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. RA Capital Management L.P. boosted its stake in Evolent Health by 125.0% during the first quarter. RA Capital Management L.P. now owns 5,736,132 shares of the technology company's stock worth $188,088,000 after buying an additional 3,187,000 shares in the last quarter. William Blair Investment Management LLC boosted its stake in Evolent Health by 35.2% during the second quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company's stock worth $96,098,000 after buying an additional 1,308,376 shares in the last quarter. First Light Asset Management LLC boosted its stake in Evolent Health by 401.5% during the second quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company's stock worth $27,634,000 after buying an additional 1,157,124 shares in the last quarter. Engaged Capital LLC boosted its stake in Evolent Health by 26.1% during the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company's stock worth $78,611,000 after buying an additional 850,000 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Evolent Health by 24.8% during the second quarter. Bank of New York Mellon Corp now owns 2,048,341 shares of the technology company's stock worth $39,164,000 after buying an additional 406,837 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on EVH. JPMorgan Chase & Co. lifted their price objective on Evolent Health from $36.00 to $45.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Citigroup cut their price objective on Evolent Health from $35.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday. Stephens reissued an "overweight" rating and set a $42.00 price objective on shares of Evolent Health in a report on Tuesday, July 30th. KeyCorp began coverage on Evolent Health in a report on Friday, October 11th. They set an "overweight" rating and a $35.00 price objective for the company. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price objective on shares of Evolent Health in a report on Tuesday, October 8th. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $38.60.

Insiders Place Their Bets

In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the sale, the chief operating officer now directly owns 63,408 shares of the company's stock, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Emily Ann Rafferty sold 8,861 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the transaction, the chief operating officer now directly owns 63,408 shares in the company, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Seth Blackley sold 187,904 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $5,637,120.00. Following the transaction, the chief executive officer now owns 411,924 shares of the company's stock, valued at $12,357,720. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 307,291 shares of company stock valued at $9,290,385. 1.60% of the stock is currently owned by insiders.

Evolent Health Price Performance

Shares of Evolent Health stock traded down $0.78 during trading on Thursday, reaching $23.36. The company's stock had a trading volume of 1,325,000 shares, compared to its average volume of 1,620,588. The stock has a 50-day moving average price of $28.17 and a two-hundred day moving average price of $25.20. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a one year low of $17.98 and a one year high of $35.00. The stock has a market capitalization of $2.71 billion, a P/E ratio of -18.68 and a beta of 1.56.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. The firm had revenue of $647.10 million during the quarter, compared to analysts' expectations of $636.46 million. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The company's quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 EPS. As a group, sell-side analysts anticipate that Evolent Health, Inc. will post 0.84 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.